Investigational drug · Phase 3
Bionetide
Also called: NA-921
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rett Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Bionetide"
First trial start
2024
Mar 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bionetide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rett Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Bionetide" as an intervention, largest first.
- To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett SyndromePivotal-lookingRecruiting
Biomed Industries, Inc.Industry
NCT06840496 · 210 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2027
Drug: Bionetide; Placebo · For: Rett Syndrome
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 18 sites in all
- To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett SyndromePivotal-lookingCompleted
Biomed Industries, Inc.Industry
NCT06849973 · 187 participants · Start Mar 15, 2024 · Primary completion Nov 22, 2024
Drug: Drug: Bionetide; Placebo · For: Rett Syndrome
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Rett Syndrome
- NTI164FEN164Phase 34 trials
Fenix Innovation Group · Rett Syndrome, Autism, Autism Spectrum Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.